Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study.

Literature DB >> 16796784

17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study.

Firas N Shadad¹, Ramesh K Ramanathan.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2006 PMID： 16796784 DOI： 10.3816/CLM.2006.n.034

Source DB: PubMed Journal: Clin Lymphoma Myeloma ISSN： 1557-9190

Keyword Cloud
Cited

× No keyword cloud information.

9 in total

Review 1. Selective Raf inhibition in cancer therapy.

Authors: Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal: Expert Opin Ther Targets Date: 2007-12 Impact factor: 6.902

2. Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90).

Authors: Lawrence C S Tam; Anna-Sophia Kiang; Matthew Campbell; James Keaney; G Jane Farrar; Marian M Humphries; Paul F Kenna; Pete Humphries
Journal: Hum Mol Genet Date: 2010-09-02 Impact factor: 6.150

3. Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging.

Authors: Mikhail Doubrovin; Jian T Che; Inna Serganova; Ekaterina Moroz; David B Solit; Lyudmila Ageyeva; Tatiana Kochetkova; Nagavarakishore Pillarsetti; Ronald Finn; Neal Rosen; Ronald G Blasberg
Journal: Mol Imaging Date: 2012-02 Impact factor: 4.488

9. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.

Authors: Wenchang Guo; Philip Reigan; David Siegel; David Ross
Journal: Drug Metab Dispos Date: 2008-07-17 Impact factor: 3.922

9 in total

17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study.

Review 1. Selective Raf inhibition in cancer therapy.

2. Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90).

3. Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging.

4. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.

5. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.

Review 6. Heat shock proteins in animal neoplasms and human tumours--a comparison.

Review 7. Heat shock protein 90 inhibition in lung cancer.

8. Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.

9. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.